Investor Outlook: Agile Therapeutics (NASDAQ:AGRX) “Buy” Rating Maintained by Analysts at Noble Financial Today

February 19, 2018 - By Peter Erickson

 Investor Outlook: Agile Therapeutics (NASDAQ:AGRX)

Investors sentiment increased to 1.35 in 2017 Q3. Its up 0.74, from 0.61 in 2017Q2. It increased, as 9 investors sold Agile Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 23.16 million shares or 7.44% more from 21.56 million shares in 2017Q2 were reported.

Geode Cap Mngmt Ltd invested in 0% or 171,318 shares. Northern holds 0% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 28,097 shares. Janney Montgomery Scott Lc owns 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 35,500 shares. Millennium Mgmt Limited Liability Corporation has 143,326 shares. Element Capital Limited Liability Corporation invested 0.02% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX). Moreover, Aisling Llc has 1.32% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 1.80M shares. Jpmorgan Chase & owns 112,773 shares. Susquehanna Interest Group Limited Liability Partnership accumulated 15,211 shares. Glenmede Na has 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX). Cormorant Asset Limited Liability owns 1.25M shares. Pura Vida Limited Com has invested 0.65% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Franklin has invested 0.01% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX). Commonwealth Of Pennsylvania School Empls Retrmt invested in 0% or 30,769 shares. Dimensional Fund Advsrs Lp holds 95,820 shares or 0% of its portfolio. Parametric Port Assoc Limited Company reported 0% stake.

Agile Therapeutics (NASDAQ:AGRX) Rating Reaffirmed

In analysts note revealed on Thursday, 9 November, Noble Financial reiterated their “Buy” rating on Agile Therapeutics (NASDAQ:AGRX) shares.

Investors sentiment increased to 1.35 in 2017 Q3. Its up 0.74, from 0.61 in 2017Q2. It increased, as 9 investors sold Agile Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 23.16 million shares or 7.44% more from 21.56 million shares in 2017Q2 were reported.

Geode Cap Mngmt Ltd invested in 0% or 171,318 shares. Northern holds 0% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 28,097 shares. Janney Montgomery Scott Lc owns 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 35,500 shares. Millennium Mgmt Limited Liability Corporation has 143,326 shares. Element Capital Limited Liability Corporation invested 0.02% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX). Moreover, Aisling Llc has 1.32% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 1.80M shares. Jpmorgan Chase & owns 112,773 shares. Susquehanna Interest Group Limited Liability Partnership accumulated 15,211 shares. Glenmede Na has 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX). Cormorant Asset Limited Liability owns 1.25M shares. Pura Vida Limited Com has invested 0.65% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Franklin has invested 0.01% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX). Commonwealth Of Pennsylvania School Empls Retrmt invested in 0% or 30,769 shares. Dimensional Fund Advsrs Lp holds 95,820 shares or 0% of its portfolio. Parametric Port Assoc Limited Company reported 0% stake.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Among 6 analysts covering Agile Therapeutics (NASDAQ:AGRX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Agile Therapeutics has $16 highest and $5.0 lowest target. $9.25’s average target is 150.68% above currents $3.69 stock price. Agile Therapeutics had 21 analyst reports since December 30, 2015 according to SRatingsIntel. The firm has “Buy” rating by Noble Financial given on Friday, July 28. Noble Financial maintained the stock with “Buy” rating in Tuesday, June 27 report. As per Friday, July 28, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, October 10. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, December 22. H.C. Wainwright maintained the shares of AGRX in report on Thursday, October 12 with “Buy” rating. The rating was downgraded by William Blair on Tuesday, December 26 to “Hold”. The firm earned “Hold” rating on Friday, December 22 by William Blair. The company was maintained on Monday, November 20 by Cantor Fitzgerald. Noble Financial maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Friday, December 22 with “Buy” rating.

The stock increased 1.10% or $0.04 during the last trading session, reaching $3.69. About 120,917 shares traded. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since February 19, 2017 and is downtrending. It has underperformed by 65.41% the S&P500.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on March, 14. They expect $-0.25 EPS, up 13.79 % or $0.04 from last year’s $-0.29 per share. After $-0.22 actual EPS reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 13.64 % negative EPS growth.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $126.15 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

More important recent Agile Therapeutics, Inc. (NASDAQ:AGRX) news were published by: Seekingalpha.com which released: “Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look” on December 27, 2017, also Prnewswire.com published article titled: “Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla …”, Seekingalpha.com published: “Agile strikes out again on US OK of contraceptive patch Twirla” on December 22, 2017. More interesting news about Agile Therapeutics, Inc. (NASDAQ:AGRX) was released by: Seekingalpha.com and their article: “Agile Therapeutics: Is This ~$3.50 ‘Busted IPO’ Worthy Of Investment …” with publication date: September 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.